Skip to main content

Advertisement

Table 1 Patient characteristics for RHYTHM study

From: [18F]Fluoromisonidazole PET in rectal cancer

Median (IQR) or number of patients (%)
Group RHYTHM B
Number 11
Age (IQR) 67 (19)
Male 9 (82)
Tumour stage (MRI)
 T2 2 (18)
 T3 9 (82)
 T4 -
Nodal stage (MRI)
 N0 4 (36)
 N1 6 (55)
 N2 1 (9)
Metastasis stage (CT)
 M0 11 (100)
Differentiation
 Well 1 (9)
 Moderate 6 (55)
 Poor 1 (9)
 Not specified 3 (27)
 Underwent TME 8 (73)
Response to CRTa
 Good 5 (45)
 Poor 6 (55)
  1. IQR interquartile range, CRT chemoradiotherapy, % percentage, TME total mesorectal excision, CT computed tomography, MRI Magnetic resonance imaging, AJCC American Joint Committee on Cancer, TRG ​tumour regression grade
  2. aGood response = AJCC TRG 0/1 with N0/1, or good clinical response; Poor response = AJCC TRG 2/3, N2 post-CRT or poor clinical response. One patient had delayed surgery due to initial good response, clinical outcome used